

The 6th Annual BioExec Institute Retreat

Wednesday 3rd – Saturday 6th March 2010

One Bal Harbour Resort & Spa, Miami, Florida

Lead Sponsor:

TVM Capital

Co-Sponsors:

***BioVista, Inc., Bristol-Myers Squibb, Edwards Angell Palmer & Dodge, LLP,
GSK, Johnson & Johnson, Merck & Co., Inc., Novartis Venture Funds, Pfizer, Inc.***

Wednesday 3rd March

19.00 **The Opening Retreat Cocktail Reception** (One Bleu Restaurant & Terrace, One Bal Harbour Resort)

Thursday 4th March

08.00 **Registration & Breakfast** (One Bleu Restaurant)

Group Discussion Sessions (Voyager Salon)

08.55 **WELCOME:** Hoda Abou-Jamra, CEO, The BioExec Institute

09.00 **HEALTHCARE REFORM & THE CHALLENGES AHEAD**

The panellists will be asked their views on the following topics:

Healthcare reform – assessing new legislation and its comparative effectiveness

What impact will the FDA have on pharmaceutical prices moving forward?

What impact will reform have on early stage biotech?

Will the US continue to lead the world in government dollars going into healthcare research and product development (NIH)?

Panellists (A-Z by surname):

James Greenwood, President & CEO, BIO

Lisa Ricciardi, Partner, Essex Woodlands Health Ventures (Moderator)

Mary Tanner, Managing Director, Peter J. Solomon Company

09.45 **CAPITAL MARKETS, IPO, and PHARMA M&A**

The panellists will be asked their views on the following topics:

Is pharma M&A going to dry up?

And what will it be driven by in 2010?

Are we going to see more structured exits with deferred payments

Why is this happening?

Panellists (A-Z by surname):

Fred Frank, Vice Chairman, Peter J Solomon Co.

Annette Grimaldi, Managing Director, BMO Capital Markets

Stelios Papadopoulos

Matthew Perry, Portfolio Manager, Biotechnology Value Fund

Helmut Schühlsler, Managing Partner, TVM Capital (Moderator)

10.30 **Coffee Break**

11.00 **VENTURE CAPITAL**

The panellists will be asked their views on the following questions:

Will VC survive? And does the industry really need to “reinvent” itself?

Where will the LPs come from?

Is pharma corporate venturing/partnering the solution for currently independent funds?

How will VCs continue to fund their previous portfolio companies and what will the role of corporate VCs be in future syndications?

How do LPs currently assess VC in the U.S. and in Europe? What makes a firm fundable?

Can pharma innovation be maintained without the classical independent VC firm?

Will VC be able to transform themselves into a good growth fund or PE?

Panellists (A-Z by surname):

Alex Barkas, Managing Director, Prospect Venture Partners (Moderator)

James Barrett, Partner, Edwards Angell Palmer & Dodge LLP

Ansbert Gadicke, Managing Director, MPM Capital

Alexandra Goll, General Partner, TVM Capital

Heather Preston, Managing Director, TPG Biotech

11.45 – 12.15	<p>OPEN ROUNDTABLE DISCUSSIONS</p> <p>These roundtable sessions are a less formal and more interactive way in which to discuss industry issues. Each table, holding approx. 8-10 persons, is facilitated by a Moderator and allocated a topic for discussion for approx. 30 minutes. The discussions will take place simultaneously and at the end of the session, the Moderators are each invited to give a brief synopsis on their table's discussion to provide comparison for the benefit of the other tables.</p>
	<p>Topics for these open roundtable sessions are taken from the Opening Panel Discussions.</p> <p>TABLE 1: <i>Healthcare Reform & The Challenges Ahead</i> Moderator 1: James Greenwood, President & CEO, BIO</p> <p>TABLE 2 & 3: <i>Capital Markets & IPO:</i> Moderator 2: Stelios Papadopoulos</p> <p><i>Pharma M&A:</i> Moderator 3: Barbara Yanni, VP & Chief Licensing Officer , Merck & Co., Inc.</p> <p>TABLE 4: <i>Venture Capital: Can VC become a successful growth capital or a PE?:</i> Helmut Schühlsler, Managing Partner, TVM Capital</p>
12.15 – 13.00	<p>OPEN ROUND TABLE SUMMARIES</p> <p>Each of the moderators will provide a summary of what their table discussed and the outcomes of these discussions.</p>
13.00	<p>Lunch (One Bleu Restaurant)</p>
Group Activities	
14.30 – 16.30	<p>Group Beach Activities and The Annual Retreat Soccer Match</p> <p>A private area has been set up for Retreat guests on the Beach with refreshments, umbrellas, and loungers. Everyone is invited to either participate in or support the annual Beach Soccer match which will kick off at <u>15.00pm</u> and, as usual, there will be champagne afterwards for the willing participants!</p>
19.00	<p>Cocktail & Dinner Reception at The Temple House</p> <p>All guests to rendezvous in the hotel foyer for 19.00pm transfer departure. Return transfer at 23.00pm back to One Bal Harbour Resort.</p>

Friday 5 th March	
08.00	Breakfast (One Bleu Restaurant)
Group Discussion Sessions (Voyager Salon)	
09.00	<p>PHARMA</p> <p>The panellists will be asked their views on the following questions: <i>How to ensure an adequate level of investment and activity in early stage work.</i> <i>The increasing emphasis in pharma on orphan diseases – what is the motivation for this and where will it lead?</i> <i>The new trend of Pharma doing corporate venturing – where is it now, how will it benefit Pharma and where will it be in 5 years? How does it interact with classical Venture Capital? Is it the solution for VC?</i> <i>New companion diagnostics and diagnostic medicine – what works and what doesn't?</i> <i>Pharmaceutical Globalization and assessing the effects of:</i> <i>Pharma looking for growth outside of the stagnated developed markets - Emerging Markets (tiered);</i> <i>Pharma looking for cost-efficiency in R&D and in production; Pharma benefiting from “economy of scale”;</i> <i>Generics moving to center stage.</i> <i>The impact of the materializing of Follow on Biologics (FOB)</i></p> <p><u>Panellists (A-Z by surname):</u> Demetrios Kydonieus, Executive Director Strategic Transaction Operations, Bristol-Myers Squibb David Nicholson, SVP, Worldwide Licensing & Knowledge Management, Merck & Co., Inc. Paul Sekhri, Head Biotech Ops Group, TPG Biotech (Moderator) Gino Santini, SVP, Eli Lilly & Co. Lauren Silverman, Managing Director, Novartis Option Fund Robert Wills, VP, Alliance Management, Pharmaceuticals Group, Johnson & Johnson</p>
09.45	<p>BIOTECH</p> <p>The panellists will be asked their views on the following questions: <i>How will biotech get funding if VC is dried up?</i> <i>Will there be any start-up funded? Is virtuality a real solution? And if yes, for what type of company?</i> <i>Are we going into an era of the service firm, instead of massive drug development? For mostly financial reasons?</i></p> <p><u>Panellists (A-Z by surname):</u> Steven Bernitz, CBO, Concert Pharmaceuticals, Inc. Torbjorn Bjerke, President & CEO, Orexo, AB (Moderator) Jens Eckstein, General Partner, TVM Capital Aris Persidis, President, BioVista Jean-Pierre Sommadossi, Chairman & CEO, Idenix Pharmaceuticals</p>
10.30	Coffee Break
11.00	<p>OPEN ROUNDTABLE DISCUSSIONS</p> <p>Each table, holding approx. 8-10 persons, is facilitated by a Moderator and allocated a topic for discussion for approx. 30 minutes. The discussions will take place simultaneously and at the end of the session, the Moderators are each invited to give a brief synopsis on their table's discussion.</p>
	<p>TABLES 1, 2 & 3: <i>Pharma:</i> Moderator 1: Robert Wills, V.P., Alliance Management, Pharmaceuticals Group, Johnson & Johnson Moderator 2: David Nicholson, SVP, Worldwide Licensing & Knowledge Management, Merck & Co., Inc.</p> <p>TABLE 3: <i>Biotech:</i> Moderator Table 4: Aris Persidis, President, BioVista</p> <p>TABLE 4: <i>Emerging Markets: Eastern Europe, Asia & ME:</i> Moderator Table 5: Helmut Schühslser, Managing Partner, TVM Capital</p>
11.30	<p>OPEN ROUND TABLE SUMMARIES</p> <p>Each of the moderators will provide a summary of what their table discussed.</p>
12.00	Lunch (One Bleu Restaurant)
Group Activities	
13.00	Golf at La Gorce Golf Club: Transfer departs from the hotel foyer at <u>13.00pm</u> . Return transfer is at 18.00pm.
14.30 – 16.00	Group Beach Activities: A private area has been set up for Retreat guests with refreshments, umbrellas and loungers, and a range of beach activities will be on offer.
19.30	Drinks Reception: (One Blue Restaurant & Terrace)
Saturday 6 th March	
10.00	Farewell Breakfast (One Bleu Restaurant)